AMG811

Phase 1Small molecule

Amgen

AMG811 is one of 10 small molecule programs targeting Discoid Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Discoid Lupus ErythematosusActive, not recruiting

Discoid Lupus ErythematosusPhase 1

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Discoid Lupus Erythematosus

#DrugCompanyPhaseTrials

Otezla

Jakafi

1 3

Anzupgo

Alnylam Pharmaceuticals

Phase 2

1 4

Thalomid

Bristol-Myers Squibb

Phase 2

1 5

Cosentyx

Novartis

Phase 2

1 6

Enbrel

IImmunex

Phase 2

2 7

Daxdilimab

Amgen

Phase 2

1 8

Raptiva

Roche

Phase 2

1 9

CC-930

Bristol-Myers Squibb

Phase 2

1 10

AMG811

Amgen

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Discoid Lupus Erythematosus1 trial

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

Terminated· Amgen logo

Amgen·Phase 1·NCT01164917·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AMG811. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMG811 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMG811. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Amgen

AMG811

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Discoid Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News